SCHEMBL302906

SCHEMBL302906

OCCn1c[c]cn1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16050529 0.75
SCHEMBL16051014 0.75
SCHEMBL16050587 0.71
SCHEMBL752654 0.70
SCHEMBL1712704 0.68 ALDH1A1 (0.35)
SCHEMBL17113615 0.67 NLRP3 (0.31)
SCHEMBL15011647 0.67 KDM4E (0.30)
SCHEMBL2520858 0.65
SCHEMBL3854710 0.65
SCHEMBL12818836 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 271 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024118887-A1 N-PHENYL-PYRAZOLO[1,5-A]PYRIDINE-3-CARBOXAMIDE DERIVATIVES AS WILD TYPE C-KIT KINASE INHIBITORS FOR THE TREATMENT OF URTICARIA BLUEPRINT MEDICINES CORPORATION (US) 2024-06-06 WO claimed
WO-2024104968-A1 PYRAZOLOPYRROLOPYRIDAZINES AND THEIR USES AS PDGFR INHIBITORS ACTELION PHARMACEUTICALS LTD (CH) 2024-05-23 WO claimed
EP-4352059-A1 TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS Incyte Corporation (US) 2024-04-17 EP claimed
US-11939331-B2 Tricyclic heterocycles as FGFR inhibitors INCYTE CORPORATION (US) 2024-03-26 US claimed
US-11897891-B2 Tricyclic heterocycles as FGFR inhibitors INCYTE CORPORATION (US) 2024-02-13 US claimed
EP-4073057-B1 NEW FYN AND VEGFR2 KINASE INHIBITORS Rottapharm Biotech Srl (IT) 2023-11-29 EP claimed
US-20230271956-A1 AMIDE DERIVATIVES MERCK PATENT GMBH (DE) 2023-08-31 US claimed
US-20230061118-A1 NEW FYN AND VEGFR2 KINASE INHIBITORS ROTTAPHARM BIOTECH S.R.L. (IT) 2023-03-02 US claimed
US-20230043835-A1 Compounds for the Treatment of Kinase-Dependent Disorders EXELIXIS, INC. 2023-02-09 US claimed
EP-4121429-A1 CONDENSED PYRIDINE DERIVASTIVES SUBSTITUED BY AMIDE FUNCTIONS AS ACSS2 INHIBITORS Merck Patent GmbH (DE) 2023-01-25 EP claimed
JP-2011526260-A 2011-10-06 JP claimed
US-20110218198-A1 Pyrrolopyridinylpyrimidin-2-ylamine derivatives MERCK PATENT GESELLSCHAFT (DE) 2011-09-08 US claimed
CN-102056926-A Pyrrolopyridinylpyrimidin-2-ylamine derivatives MERCK PATENT GMBH 2011-05-11 CN claimed
EP-2291375-A1 PYRROLOPYRIDINYLPYRIMIDIN-2-YLAMINE DERIVATIVES Merck Patent GmbH (DE) 2011-03-09 EP claimed
WO-2011025951-A1 RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF ARRAY BIOPHARMA INC. (US) 2011-03-03 WO claimed
US-20100152159-A1 IMIDAZOPYRAZINE SYK INHIBITORS Kronos Bio, Inc. 2010-06-17 US claimed
WO-2010068258-A1 IMIDAZOPYRAZINE SYK INHIBITORS CGI PHARMACEUTICALS, INC. (US) 2010-06-17 WO claimed
WO-2010000364-A1 PYRROLOPYRIDINYLPYRIMIDIN-2-YLAMINE DERIVATIVES MERCK PATENT GMBH (DE) 2010-01-07 WO claimed
US-20070275968-A1 Substituted Biphenyl Derivative SANKYO COMPANY, LIMITED (JP) 2007-11-29 US claimed
EP-1798229-A1 SUBSTITUTED BIPHENYL DERIVATIVE Sankyo Company, Limited (JP) 2007-06-20 EP claimed